2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-Z6663
    Salbutamol methyl ether 870076-72-5 98%
    Salbutamol methyl ether is a derivative of Salbutamol (HY-B1037) used as an immunohapten to obtain antibodies.
    Salbutamol methyl ether
  • HY-Z6838
    1-[3-(4-tert-Butylbenzoyl)propyl]-4-hydroxypiperidine 97928-18-2 98%
    1-[3-(4-tert-Butylbenzoyl)propyl]-4-hydroxypiperidine is an intermediate of Ebastine (HY-B0674). Ebastine is an orally active, second-generation histamine H1 receptor antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research.
    1-[3-(4-tert-Butylbenzoyl)propyl]-4-hydroxypiperidine
  • HY-Z7640
    4-Desmethyl-2-methyl celecoxib 170569-99-0 98%
    4-Desmethyl-2-methyl celecoxib (Compound 1g) is an orally active and selective Cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 0.069 μM. 4-Desmethyl-2-methyl celecoxib shows anti-inflammatory, analgesic, and antipyretic activities. 4-Desmethyl-2-methyl celecoxib can reduces the synthesis of prostaglandins. 4-Desmethyl-2-methyl celecoxib is promising for research of inflammatory diseases and pain-related diseases, such as rheumatoid arthritis and osteoarthritis.
    4-Desmethyl-2-methyl celecoxib
  • HY-Z7659
    Lansoprazole sulfone N-Oxide 953787-54-7 98%
    Lansoprazole sulfone N-Oxide (Comound 3) is the overoxidized by-product found in the synthesis of the proton pump inhibitor Lansoprazole (HY-13662). Lansoprazole sulfone N-Oxide is promising for research of duodenal and gastric ulcers, reflux oesophagitis, and Zollinger–Ellison syndrome.
    Lansoprazole sulfone N-Oxide
  • HY-Z7660
    Lansoprazole N-oxide 213476-12-1 98%
    Lansoprazole N-oxide (Comound 2) is the overoxidized by-product found in the synthesis of the proton pump inhibitor Lansoprazole (HY-13662). Lansoprazole N-oxide is promising for research of duodenal and gastric ulcers, reflux oesophagitis, and Zollinger–Ellison syndrome.
    Lansoprazole N-oxide
  • HY-Z8025
    Deprodone 20423-99-8 98%
    Deprodone is an active compound. Deprodone inhibits key processes such as bacterial cell wall synthesis by interacting with the hydrolase and transferase proteins of methicillin-resistant Staphylococcus aureus (MRSA). Deprodone is used in research on anti-MRSA infection, inflammatory skin disorders, bowel disease, and fatty acid metabolism disorders.
    Deprodone
  • HY-Z8648
    Δ14-Triamcinolone acetonide 1260149-96-9 98%
    Δ14-Triamcinolone acetonide is a potential impurity. Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis.
    Δ14-Triamcinolone acetonide
  • HY-10011R
    SCH 563705 (Standard) 473728-58-4 98%
    SCH 563705 (Standard) is the analytical standard of SCH 563705 (HY-10011). This product is intended for research and analytical applications. SCH 563705 is a potent and orally available CXCR2 and CXCR1 antagonist, with IC50s of 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively.
    SCH 563705 (Standard)
  • HY-100153
    48740 RP 93363-11-2 98%
    48740 RP ((Rac)-RP-55778) is a platelet-activating factor (PAF) antagonist.
    48740 RP
  • HY-10019R
    Varenicline (Standard) 249296-44-4 98%
    Varenicline (Standard) is the analytical standard of Varenicline. This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
    Varenicline (Standard)
  • HY-10020R
    Varenicline Hydrochloride (Standard) 230615-23-3 98%
    Varenicline (Hydrochloride) (Standard) is the analytical standard of Varenicline (Hydrochloride). This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
    Varenicline Hydrochloride (Standard)
  • HY-100274
    Adenosine antagonist-1 431040-19-6 99.79%
    Adenosine antagonist-1 is an adenosine A3 receptor (AA3R) antagonist with anti-inflammatory activity.
    Adenosine antagonist-1
  • HY-100278
    AKP-001 897644-83-6 98%
    AKP-001 is an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). AKP-001 can inhibit the production of inflammatory cytokines and can be used for research in rheumatoid arthritis and inflammatory bowel disease.
    AKP-001
  • HY-100283
    CGS 15435 95853-92-2 98%
    CGS 15435, a potent thromboxane (TxA2) synthetase inhibitor with an IC50 of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI2 synthetase and lipoxygenase enzymes.
    CGS 15435
  • HY-100284
    Thiazolidinone-Derivatives-1 136272-75-8 99.79%
    Thiazolidinone-Derivatives-1 is an antiulcer agent which inhibits the secretion of gastric acid.
    Thiazolidinone-Derivatives-1
  • HY-100316
    CP-96486 139401-45-9 98%
    CP-96486 is a potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonist with Kis of 20 and 24 nM, respectively.
    CP-96486
  • HY-10037R
    Quiflapon (Standard) 136668-42-3 98%
    Quiflapon (Standard) is the analytical standard of Quiflapon. This product is intended for research and analytical applications. Quiflapon (MK-591) is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50?of 1.6 nM in a FLAP binding assay. Quiflapon is also a potent and orally active?Leukotriene biosynthesis (LT)?inhibitor, shows IC50?values of 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively. Quiflapon induces cell apoptosis.
    Quiflapon (Standard)
  • HY-10046R
    Plerixafor (Standard) 110078-46-1 98%
    Plerixafor (Standard) is the analytical standard of Plerixafor. This product is intended for research and analytical applications. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM.
    Plerixafor (Standard)
  • HY-10053B
    Maropitant citrate 862543-54-2 98%
    Maropitant citrate is an orally active NK1 receptor antagonist. Maropitant citrate prevents vomiting and inhibits ulcerative dermatitis.
    Maropitant citrate
  • HY-100640
    Roflumilast Impurity E 1391052-76-8 98.37%
    Roflumilast Impurity E is the impurity of Roflumilast. Roflumilast(Daliresp) is a agent which acts as a selective and long-acting inhibitor of the enzyme PDE-4 with an IC50 value of 0.8 nM.
    Roflumilast Impurity E
製品番号 製品名 / Synonyms Application Reactivity